Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 52

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 52
---
or the Company’s successor) assumes in writing all
of the Company’s obligations under the Certificate of Designations and the other Transaction Documents (as defined in the Series D
Certificate of Designations).

Voting Rights. The
holders of the Series D Preferred Stock shall have no voting power and no right to vote on any matter at any time, either as a separate
series or class or together with any other series or class of share of capital stock, and shall not be entitled to call a meeting of such
holders for any purpose nor shall they be entitled to participate in any meeting of the holders of Common Stock, except as provided in
the Certificate of Designations (or as otherwise required by applicable law).

Covenants. The Series D
Certificate of Designations contains a variety of obligations on the Company’s part not to engage in specified activities. In particular,
the Company will not, and will cause the Company’s subsidiaries to not, redeem, repurchase or declare any dividend or distribution
on any of the Company’s capital stock (other than as required under the Series D Certificate of Designations) and will not
incur any indebtedness other than ordinary course trade payables or, subject to certain exceptions, incur any liens. In addition, the
Company will not issue any preferred stock or issue any other securities that would cause a breach or default under the Series D
Certificate of Designations.

Reservation Requirements.
So long as any Series D Preferred Stock remains outstanding, the Company shall at all times reserve at least 250% of the number of
shares of Common Stock as shall from time to time be necessary to effect the conversion of all Series D Preferred Stock then outstanding.

On April 21, 2025, the Company
entered into a Securities Purchase Agreement (the “Fourth Securities Purchase Agreement”) with certain accredited investors.
Pursuant to the Fourth Securities Purchase Agreement, up to 10,000 shares of the Company’s Series D Preferred Stock shall be purchased
for an aggregate purchase price of up to $8 million in one or more closings.

<div align='center'>20</div>

On April 22, 2025, pursuant
to the Fourth Securities Purchase Agreement, the Company issued and sold, and the investors purchased, in a private placement (the “Fourth
PIPE Financing”), 6,250 shares of the Series D Preferred Stock in exchange for the receipt of 1,000,279 shares of Series D Preferred
Stock of Stella Diagnostics, Inc, (the “Stella